Effect of Lilalutide Injection Combined with Daggligin in the Treatment of Type 2 Diabetes and Its Influence on Blood Glucose Indicators of Patients
Objective To explore the clinical efficacy of liraglutide injection combined with dagelin in patients with type 2 diabetes.Methods 84 patients with type 2 diabetes treated in Linyi Hospital of Traditional Chinese Medicine from August 2021 to May 2023 were selected as the study objects,and were divided into a control group and an observation group according to random number table method,with 42 cases in each group.The control group was treated with dagliprazin,and the observation group was treated with liraglutide injection on the basis of the control group.The clinical efficacy,blood glucose index,islet function and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of HBA1c,fasting blood glucose and 2 h postprandial blood glucose in two groups were lower than before treatment,and the observation group were lower than the control group,the difference was statistically significant(P＜0.05).After treatment,islet β cell function,fasting insulin and 2 h postprandial insulin levels in two groups were higher than before treatment,and observation group were higher than control group,the difference was statistically significant(P＜0.05).After treatment,insulin resistance index in 2 groups was lower than before treatment,and observation group was lower than control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The clinical effect of Lilalutide injection combined with Daggligin in the treatment of type 2 diabetes is definite,which can effectively improve the blood glucose index and pancreatic islet function index of patients,and has better safety.
Type 2 diabetesLiraglutide InjectionDapagliflozinClinical efficacyBlood glucose indicators
NETL
NSTL
万方数据
